AMGEN REGULATORY CONSULTING, SL – Trademark Portfolio
Entity Type: 99
AMGEN REGULATORY CONSULTING, SL holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. The portfolio also extends into Class 45 (Legal & Security Services) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include ATOVA.
Paseo de Gracia, 50, 5
E-08007 Barcelona
Showing of trademarks Trademarks
Trademark Classifications
AMGEN REGULATORY CONSULTING, SL's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Legal services; security services for the protection of property and individuals
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does AMGEN REGULATORY CONSULTING, SL have?
AMGEN REGULATORY CONSULTING, SL has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does AMGEN REGULATORY CONSULTING, SL file in?
AMGEN REGULATORY CONSULTING, SL files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.
What are AMGEN REGULATORY CONSULTING, SL's most well-known trademarks?
AMGEN REGULATORY CONSULTING, SL's registered trademark portfolio includes well-known marks such as ATOVA. These are among 1 currently registered trademark in the portfolio.
What is AMGEN REGULATORY CONSULTING, SL's trademark registration success rate?
AMGEN REGULATORY CONSULTING, SL has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.